Viking Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	165.81	26.68	55.52	36.63	26.37
Short-Term Investments	539.93	875.94	306.56	118.85	175.73
Cash & Short-Term Investments	705.74	902.61	362.08	155.49	202.1
Cash Growth	-21.81%	149.29%	132.87%	-23.07%	-18.63%
Prepaid Expenses	1.81	1.13	2.52	3.41	0.62
Other Current Assets	8.05	3.48	2.62	8.14	7.81
Total Current Assets	715.6	907.22	367.23	167.04	210.53
Property, Plant & Equipment	0.09	1	1.13	1.42	0.03
Long-Term Deferred Charges	-	0.06	0.11	0.04	0.08
Other Long-Term Assets	0.05	0.05	0.03	0.03	0.03
Total Assets	715.73	908.32	368.49	168.53	210.66
Accounts Payable	53.25	9.81	7.51	8.53	1.44
Accrued Expenses	23.28	17.11	11.3	13.11	7.31
Current Portion of Leases	0.14	0.49	0.32	0.3	0.03
Total Current Liabilities	76.67	27.41	19.14	21.95	8.78
Long-Term Leases	-	0.63	0.94	1.26	-
Total Liabilities	76.67	28.04	20.07	23.21	8.78
Common Stock	0	0	0	0	0
Additional Paid-In Capital	1,486	1,369	733.55	445.27	425.61
Retained Earnings	-847.55	-487.91	-377.94	-292.05	-223.18
Treasury Stock	-	-	-6.8	-6.8	-
Comprehensive Income & Other	0.38	-0.79	-0.39	-1.1	-0.55
Shareholders' Equity	639.06	880.28	348.42	145.32	201.88
Total Liabilities & Equity	715.73	908.32	368.49	168.53	210.66
Total Debt	0.14	1.12	1.26	1.56	0.03
Net Cash (Debt)	705.6	901.49	360.82	153.92	202.07
Net Cash Growth	-21.73%	149.85%	134.42%	-23.83%	-18.53%
Net Cash Per Share	6.26	8.27	3.82	2.00	2.62
Filing Date Shares Outstanding	115.55	112.25	100.49	78.42	78.36
Total Common Shares Outstanding	114.79	111.57	100.11	78.26	78.25
Working Capital	638.93	879.8	348.09	145.09	201.75
Book Value Per Share	5.57	7.89	3.48	1.86	2.58
Tangible Book Value	639.06	880.28	348.42	145.32	201.88
Tangible Book Value Per Share	5.57	7.89	3.48	1.86	2.58

Source: S&P Global Market Intelligence. Standard template. Financial Sources.